Stock Track | Ligand Pharmaceuticals Plunges 7.33% in Pre-Market After Q1 Earnings and Sales Miss Estimates

Stock Track05-07

Ligand Pharmaceuticals (LGND) experienced a significant pre-market decline of 7.33% on Thursday following the release of its first-quarter 2026 financial results.

The stock's decline appears to be a direct reaction to the company's quarterly report, which showed adjusted earnings per share of $1.63, missing the analyst consensus estimate of $1.82 by 10.44%. Furthermore, quarterly sales of $51.722 million fell short of the $58.696 million estimate by 11.88%. While the company narrowed its GAAP net loss year-over-year, the report also highlighted a widened non-operating expense, including a $49.2 million non-cash loss related to Pelthos investments, and a decline in Captisol sales.

Despite the quarterly miss, the company reaffirmed its full-year 2026 guidance for adjusted earnings and royalty revenue, and is targeting the completion of its acquisition of XOMA Royalty in the third quarter.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1142258330?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-07 21:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1142258330","market":"sg","top_or_hot":-1,"title":"Stock Track | Ligand Pharmaceuticals Plunges 7.33% in Pre-Market After Q1 Earnings and Sales Miss Estimates","media":"Stock Track","content":"<p>Ligand Pharmaceuticals (LGND) experienced a significant pre-market decline of 7.33% on Thursday following the release of its first-quarter 2026 financial results.</p><p>The stock's decline appears to be a direct reaction to the company's quarterly report, which showed adjusted earnings per share of $1.63, missing the analyst consensus estimate of $1.82 by 10.44%. Furthermore, quarterly sales of $51.722 million fell short of the $58.696 million estimate by 11.88%. While the company narrowed its GAAP net loss year-over-year, the report also highlighted a widened non-operating expense, including a $49.2 million non-cash loss related to Pelthos investments, and a decline in Captisol sales.</p><p>Despite the quarterly miss, the company reaffirmed its full-year 2026 guidance for adjusted earnings and royalty revenue, and is targeting the completion of its acquisition of XOMA Royalty in the third quarter.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Ligand Pharmaceuticals Plunges 7.33% in Pre-Market After Q1 Earnings and Sales Miss Estimates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Ligand Pharmaceuticals Plunges 7.33% in Pre-Market After Q1 Earnings and Sales Miss Estimates\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-05-07 21:15</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Ligand Pharmaceuticals (LGND) experienced a significant pre-market decline of 7.33% on Thursday following the release of its first-quarter 2026 financial results.</p><p>The stock's decline appears to be a direct reaction to the company's quarterly report, which showed adjusted earnings per share of $1.63, missing the analyst consensus estimate of $1.82 by 10.44%. Furthermore, quarterly sales of $51.722 million fell short of the $58.696 million estimate by 11.88%. While the company narrowed its GAAP net loss year-over-year, the report also highlighted a widened non-operating expense, including a $49.2 million non-cash loss related to Pelthos investments, and a decline in Captisol sales.</p><p>Despite the quarterly miss, the company reaffirmed its full-year 2026 guidance for adjusted earnings and royalty revenue, and is targeting the completion of its acquisition of XOMA Royalty in the third quarter.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LGND","symbol_name":"Ligand Pharmaceuticals Inc.","start_time":0,"source_url":"","article_id":"1142258330","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1142258330","pubTimestamp":1778159707,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Ligand Pharmaceuticals (LGND) experienced a significant pre-market decline of 7.33% on Thursday following the release of its first-quarter 2026 financial results.The stock's decline appears to be a...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LGND":"Ligand Pharmaceuticals Inc."},"translate_title":"个股追踪|Ligand Pharmaceuticals盘前暴跌7.33%因Q1盈利和销售不及预期","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LGND":1},"content_text":"Ligand Pharmaceuticals (LGND) experienced a significant pre-market decline of 7.33% on Thursday following the release of its first-quarter 2026 financial results.The stock's decline appears to be a direct reaction to the company's quarterly report, which showed adjusted earnings per share of $1.63, missing the analyst consensus estimate of $1.82 by 10.44%. Furthermore, quarterly sales of $51.722 million fell short of the $58.696 million estimate by 11.88%. While the company narrowed its GAAP net loss year-over-year, the report also highlighted a widened non-operating expense, including a $49.2 million non-cash loss related to Pelthos investments, and a decline in Captisol sales.Despite the quarterly miss, the company reaffirmed its full-year 2026 guidance for adjusted earnings and royalty revenue, and is targeting the completion of its acquisition of XOMA Royalty in the third quarter.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1142258330","isCrawlerRequest":true}